Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05012397 · OUTCOME

Growth Modulation Index (GMI)

Milademetan in Advanced/Metastatic Solid Tumors · Source last updated 2024-10-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Inter-Quartile Range
Time frame
From the start date of the most recent prior line of therapy to the PD date on the study; up to 23.5 months

What was measured

GMI defined as the ratio of Time to Progression (TTP) with the nth line of therapy (TTPn; here defined as milademetan) to the most recent prior line of therapy (TTPn-1)

Analysis population: The efficacy analysis is conducted in all participants within the Centrally confirmed population (CCP).

Groups in this outcome

Milademetan (RAIN-32)

260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Milademetan (RAIN-32)31

Reported measurements

Source class 1
Values in months · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Milademetan (RAIN-32)0.76Not reported0.470.98Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.47
        upper Limit
        0.98
        value
        0.76
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
GMI defined as the ratio of Time to Progression (TTP) with the nth line of therapy (TTPn; here defined as milademetan) to the most recent prior line of therapy (TTPn-1)
dispersion Type
Inter-Quartile Range
groups
  1. description
    260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
    id
    OG000
    title
    Milademetan (RAIN-32)
param Type
MEDIAN
population Description
The efficacy analysis is conducted in all participants within the Centrally confirmed population (CCP).
reporting Status
POSTED
time Frame
From the start date of the most recent prior line of therapy to the PD date on the study; up to 23.5 months
title
Growth Modulation Index (GMI)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice